Seeking Alpha

In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of...

In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of 2030, Amarin (AMRN -0.7%) says it submitted a Supplemental New Drug Application to the FDA seeking approval for Chemport, Inc. as an additional Vascepa active pharmaceutical ingredient supplier. The submission is part of the company's goal to expand and protect its manufacturing supply chain.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)